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Introduction
In patients with previously stable hypertension, some
non-selective non-steroidal anti-inﬂammatory drugs
(NSAIDs) and selective cyclo-ooxygenase-2 (COX-2)
inhibitors have been shown to increase systolic blood
pressure and diastolic blood pressure (SBP and DBP)
(1–4). However, these increases in BP can vary
according to the individual NSAID used (2,5) and
even between COX-2 inhibitors (6). Previous studies
have reported that NSAIDs (1,2,7,8) and the COX-2
inhibitor rofecoxib (9) interact with BP control in
patients treated with antihypertensive medications
and patients treated with some classes of antihyper-
tensive medications seem to be affected to a greater
degree than others (4,8).
Lumiracoxib (Prexige
 , Novartis Pharma AG,
Basel, Switzerland) is a novel selective COX-2 inhibi-
tor that has been shown to have a lower 24-h mean
systolic ambulatory BP (MSABP) proﬁle (5 mmHg
lower) than ibuprofen in an ambulatory BP monitor-
ing (ABPM) study in osteoarthritis (OA) patients
aged ‡ 50 years with controlled hypertension (10,11).
To examine whether the BP proﬁles of lumiracoxib
and ibuprofen differed in patients treated with differ-
ent classes of antihypertensive medications, a post
hoc analysis of this ambulatory BP study was
conducted.
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SUMMARY
Aims: To examine whether the blood pressure (BP) proﬁles of lumiracoxib and
high-dose ibuprofen differed in patients treated with different classes of antihyper-
tensive medications. Methods: A 4-week, multicentre, randomised, double-blind
study has compared the effects of lumiracoxib 100 mg once daily (od) (n = 394)
and ibuprofen 600 mg three times daily (tid) (n = 393) on ambulatory BP in
osteoarthritis (OA) patients with controlled hypertension. Here, we present sub-
group analyses for patients receiving different antihypertensive classes. The primary
outcome was a comparison of the change in 24-h mean systolic ambulatory BP
(MSABP) from baseline to week 4. Patients receiving angiotensin receptor blockers
(ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) represented the largest
subgroups receiving antihypertensive monotherapy. Results: For patients receiving
an ARB monotherapy, the least squares mean (LSM) 24-h MSABP at week 4 fell
with lumiracoxib 100 mg od and increased with ibuprofen 600 mg tid, creating an
estimated treatment difference of 8.1 mmHg in favour of lumiracoxib (p < 0.001).
For patients receiving an ACEI and a beta-blocker monotherapy, the estimated
treatment difference was 8.2 mmHg (p < 0.001) and 5.8 mmHg (p = 0.002) in
favour of lumiracoxib respectively. These treatment differences were greater than
observed in the overall population (5.0 mmHg in favour of lumiracoxib). In patients
receiving diuretics or calcium channel blockers, treatment differences in MSABP
were smaller and not statistically signiﬁcant, although they remained in favour of
lumiracoxib. Conclusion: Lumiracoxib 100 mg od resulted in less destabilisation
of BP than high-dose ibuprofen 600 mg tid, and this effect was the greatest in
subgroups treated with drugs blocking the renin-angiotensin system.
What’s known
• Non-steroidal anti-inﬂammatory drugs (NSAIDs)
and COX-2 inhibitors are known to increase BP
in patients receiving antihypertensive medication.
• Increases in BP can vary according to the
individual NSAID or COX-2 inhibitors used.
What’s new
• The lumiracoxib (COX-2 inhibitor), does not
increase BP compared with high-dose ibuprofen
(an NSAID) in patients with OA and well-
controlled hypertension.
• Differences in BP between lumiracoxib and
ibuprofen vary with the class of antihypertensive
agent.
• Considering both antihypertensive and OA pain
medications might help minimise destabilisation
of BP.
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Study design
This was a post hoc analysis of a 4-week, multicen-
tre, randomised, double-blind, double-dummy, par-
allel-group study conducted in 79 centres in nine
countries (the USA, Austria, Belgium, Finland,
France, Germany, Sweden, the UK, and Brazil). The
original trial was an ABPM study in patients rando-
mised to receive lumiracoxib 100 mg once daily
(od) or high-dose ibuprofen 600 mg three times
daily (tid). The study design and results have been
published previously (10,11). Ibuprofen 600 mg was
chosen as the comparator as it is an approved pre-
scription-strength drug for the treatment of OA in
most of the European countries and a tid was con-
sidered to be the most commonly prescribed dosing
frequency (12). For lumiracoxib, the prescription
dose of 100 mg od has been shown to provide at
least comparable efﬁcacy to celecoxib 200 mg od
(13,14). Celecoxib 200 mg od in turn has been
shown to have efﬁcacy similar to ibuprofen 800 mg
tid (15). Therefore, lumiracoxib 100 mg od can be
considered as (at least) comparable in terms of efﬁ-
cacy, which would in turn be a conservative
approach for comparison of safety as done in our
study. Thus, differences in BP proﬁle observed
appear to be relevant.
Brieﬂy, during a 1-week run-in phase, eligible
patients had their current analgesic therapy washed
out and replaced with paracetamol (acetaminophen)
1000 mg tid. At the end of the run-in period,
patients underwent ABPM for 24 h. Patients who
were at least 80% compliant with the run-in paracet-
amol regimen (paracetamol tablets were dispensed at
the beginning of the washout phase and patients
returned remaining tablets at the end of the washout
phase for compliance to be assessed by pill counts)
and whose ABPM data met the quality control crite-
ria were then randomised in equal ratio to receive
lumiracoxib 100 mg od or ibuprofen 600 mg tid
orally for 4 weeks, and paracetamol treatment was
stopped. Ambulatory BP monitors were ﬁtted by
experienced individuals and three to six correlation
readings were performed to ensure that mean systolic
and diastolic ambulatory BP was ±10⁄7 mmHg of
the mean ofﬁce sphygmomanometer BP readings.
Quality control procedures were performed automat-
ically by the ambulatory BP monitor using the corre-
lation readings. During the 4-week treatment period,
no changes were allowed to the patient’s usual anti-
hypertensive treatment, and no paracetamol rescue
medication, NSAID or other potentially BP-modify-
ing treatments were permitted.
Patients
Male and female outpatients (aged ‡ 50 years) were
included if they had symptomatic primary OA of the
hand, hip, knee or spine, pain in the target joint
classiﬁed as mild, moderate or severe according to a
5-point categorical scale, and were expected to need
NSAID treatment for at least 6 weeks. Patients were
also required to have controlled hypertension (mean
sitting SBP < 140 mmHg and mean sitting DBP
< 90 mmHg, measured as the mean of three seated
standard ofﬁce sphygmomanometer readings taken at
1-min intervals after a 5-min rest), to have been tak-
ing the same regular ﬁxed dosing regimen of antihy-
pertensive medication(s) for ‡ 3 consecutive months
prior to screening and who were not expected to
adjust antihypertensive medication during the study.
Assessments
Ambulatory BP was measured every 20 min using a
‘Spacelabs 90207 ABP Monitor’ (Spacelabs, Issaquah,
WA, USA) during the 24-h at baseline (prior to
randomisation) and after week 4 of treatment (study
end). For the purpose of calibration of the device,
three to six readings were taken in patients in a seated
position. If the mean difference between three simulta-
neous ABP monitor and ofﬁce mercury column
systolic BP readings were outside ±10 mmHg and
diastolic BP readings outside ±7 mmHg, the ABPM
unit was reprogrammed and the calibration repeated.
The primary objective was the comparison of the
change from baseline in 24-h MSABP between the
lumiracoxib and ibuprofen treatment groups at week
4. Secondary end-points included change from base-
line in 24-h mean diastolic ambulatory BP
(MDABP); change from baseline in MSABP and
MDABP during the daytime (> 06:00 to 22:00);
change from baseline in MSABP and MDABP during
the night-time (> 22:00 to 06:00); the percentage of
patients with a clinically relevant increase in ambula-
tory BP (increase of ‡ 5 mmHg in 24-h MDABP
and⁄or increase of ‡ 10 mmHg in 24-h MSABP);
and the percentage of patients with uncontrolled
hypertension (increase in 24-h mean ambulatory BP
from < 130⁄80 mmHg at baseline to ‡ 130 mmHg
and⁄or ‡ 80 mmHg after 4 weeks of treatment). The
deﬁnition for uncontrolled hypertension as assessed
by ambulatory BP was lower than the ofﬁce cuff
measurement used to screen patients as ABP mea-
surements are typically lower than ofﬁce cuff BP
measurements.
Statistics
Sample size calculations have been reported previously
(10,11). All BP evaluations were performed on the
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mised patients who received ‡ 1 dose of the study
medication and successfully completed the postbase-
line ABPM. The BP changes were adjusted for centre
and baseline level of blood pressure (BP). The change
from baseline in 24-h MSABP and MDABP, and day-
time and night-time MSABP and MDABP were all
analysed using an analysis of covariance (ANCOVA)
with treatment as main effect and the appropriate
baseline measure as a covariate. Additional analyses
(summary statistics) were also carried out for the
change from baseline at week 4 in 24 h MSABP in the
following subgroup: gender (male⁄female); Age
(£ 64 years⁄65–74 years⁄‡75 years); race (White⁄
Caucasian, Black⁄African American, Hispanic, other).
Signiﬁcant effect modiﬁers were included in the
model. Data are presented as least squares means
(LSMs) and 95% conﬁdence intervals (CIs). Multiple
logistic regression models were used for clinically rele-
vant increase in ABP and incidence of uncontrolled
hypertension using baseline 24-h MSABP and baseline
24-h MDABP as covariates.
A post hoc analysis was conducted for patients
receiving angiotensin receptor blockers (ARBs), angio-
tensin-converting enzyme inhibitors (ACEIs), beta-
blockers, calcium channel blockers or diuretics as
monotherapy, and also for patients receiving any treat-
ment with these antihypertensive agents, including
monotherapy or free and ﬁxed-dose combinations.
Results
A total of 787 patients were randomised in the
ABPM study. All patients in the overall population
were accounted for in the subsequent post hoc sub-
group analyses of patients receiving ARBs, ACEIs,
beta-blockers, calcium channel blockers or diuretics
as monotherapy and patients receiving any treatment
with these classes either as monotherapy or in free or
ﬁxed-dose combinations. The analyses of interest
were those patients receiving monotherapy for each
antihypertensive class. Our analyses focus on the use
of ARBs or ACEIs as monotherapy because these
populations had the greatest number of patients in
the monotherapy subgroups and therefore provided
the most robust data. Data on any use of these
antihypertensive agents are provided only for the
primary end-point.
In the ITT population, fewer patients received
any antihypertensive monotherapy (lumiracoxib,
n = 166; ibuprofen, n = 150) than combinations of
antihypertensive agents (lumiracoxib, n = 227 and
ibuprofen, n = 239). An ARB monotherapy was
received by 57 and 48 patients randomised to
lumiracoxib and ibuprofen, respectively. Angioten-
sin-converting enzyme inhibitors were the only
antihypertensive medications in 42 patients receiv-
ing lumiracoxib and 40 patients taking ibuprofen.
Details of patient disposition for patients receiving
ARBs or ACEIs as monotherapy are presented in
Table 1.
Baseline demographic and background charac-
teristics were similar between treatment groups for
patients receiving an ARB or an ACEI as mono-
therapy (Table 2). In addition, baseline SBP
and DBP were similar between treatment groups
in patients receiving an ARB or an ACEI mono-
therapy.
Table 1 Patient disposition for patients receiving angiotensin receptor blocker or angiotensin-converting enzyme
inhibitor monotherapy
ARB monotherapy ACEI monotherapy
Lumiracoxib
100 mg od
(N = 57)
Ibuprofen
600 mg
tid (N = 48)
Lumiracoxib
100 mg od
(N = 42)
Ibuprofen
600 mg
tid (N = 40)
Completed, n (%) 53 (93.0) 47 (97.9) 39 (92.9) 38 (95.0)
Discontinued, n (%) 4 (7.0) 1 (2.1) 3 (7.1) 2 (5.0)
Death 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Adverse event 2 (3.5)* 0 (0.0) 1 (2.4) 0 (0.0)
Unsatisfactory therapeutic effect 1 (1.8) 0 (0.0) 1 (2.4) 0 (0.0)
Subject withdrew consent 0 (0.0) 0 (0.0) 0 (0.0) 2 (5.0)
Protocol violation 1 (1.8) 1 (2.1) 0 (0.0) 0 (0.0)
Administrative problems 0 (0.0) 0 (0.0) 1 (2.4) 0 (0.0)
*Upper abdominal pain (n = 1), retinal detachment (n = 1).
Bells palsy (n = 1).
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; od, once daily; tid, thrice daily.
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Estimated treatment differences in 24-h MSABP for
ARBs, ACEIs, beta-blockers, calcium channel block-
ers, diuretics and all antihypertensive agents as
monotherapy, and for these antihypertensive classes
including free and ﬁxed-dose combinations, are listed
in Table 3. For patients receiving an ARB monother-
apy, the LSM change from baseline in 24-h MSABP
after a 4-week treatment fell by 3.5 mmHg with
lumiracoxib 100 mg od and increased by 4.6 mmHg
with ibuprofen 600 mg tid, resulting in a statistically
signiﬁcant estimated treatment difference of
8.1 mmHg in favour of lumiracoxib (Figure 1A;
Table 3). Figure 2 shows MSABP for lumiracoxib
Table 2 Baseline demographics and disease characteristics for patients receiving an angiotensin receptor blockers or an
angiotensin-converting enzyme inhibitor monotherapy
Parameter
ARB monotherapy ACEI monotherapy
Lumiracoxib
100 mg od
(N = 57)
Ibuprofen
600 mg tid
(N = 48)
Lumiracoxib
100 mg od
(N = 42)
Ibuprofen600 mg
tid (N = 40)
Age (years), mean ± SD 64.3 ± 8.4 64.6 ± 9.0 64.1 ± 7.6 61.0 ± 6.7
Range (min–max) 50–86 50–85 50–83 50–77
Age group, n (%)
£ 64 years 30 (52.6) 24 (50.0) 23 (54.8) 28 (70.0)
65–74 years 19 (33.3) 16 (33.3) 15 (35.7) 11 (27.5)
‡ 75 years 8 (14.0) 8 (16.7) 4 (9.5) 1 (2.5)
Gender, n (%)
Female 41 (71.9) 35 (72.9) 22 (52.4) 28 (70.0)
Male 16 (28.1) 13 (27.1) 20 (47.6) 12 (30.0)
Race, n (%)
Caucasians 56 (98.2) 45 (93.8) 38 (90.5) 39 (97.5)
Black⁄African Americans 1 (1.8) 2 (4.2) 1 (2.4) 1 (2.5)
Others 0 (0.0) 1 (2.1) 3 (7.1) 0 (0.0)
Duration of OA (years), mean ± SD 4.9 ± 5.3 6.7 ± 7.0 4.5 ± 6.0 5.0 ± 5.3
OA pain, n (%)
Mild 5 (8.8) 6 (12.5) 9 (21.4) 10 (25.0)
Moderate 31 (54.4) 23 (47.9) 19 (45.2) 14 (35.0)
Severe 21 (36.8) 19 (39.6) 14 (33.3) 16 (40.0)
Patient’s global assessment of disease activity, n (%)
Very good 0 (0.0) 1 (2.1) 0 (0.0) 4 (10.0)
Good 6 (10.5) 9 (18.8) 12 (28.6) 4 (10.0)
Fair 33 (57.9) 30 (62.5) 18 (42.9) 22 (55.0)
Poor 18 (31.6) 8 (16.7) 12 (28.6) 10 (25.0)
Very poor 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Physician’s global assessment of disease activity, n (%)
Very good 1 (1.8) 0 (0.0) 0 (0.0) 0 (0.0)
Good 2 (3.5) 6 (12.5) 8 (19.0) 12 (30.0)
Fair 41 (71.9) 31 (64.6) 26 (61.9) 20 (50.0)
Poor 13 (22.8) 11 (22.9) 8 (19.0) 8 (20.0)
Very poor 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Duration of hypertension (years), mean ± SD 6.9 ± 6.6 6.2 ± 5.9 7.5 ± 7.8 6.3 ± 5.4
Sitting BP* (mmHg), mean ± SD
Systolic 130.5 ± 7.2 129.1 ± 8.5 131.1 ± 6.5 129.7 ± 10.0
Diastolic 77.8 ± 7.0 77.7 ± 8.0 78.9 ± 6.0 77.8 ± 6.8
24-h ambulatory BP (mmHg), mean ± SD
Systolic 127.2 ± 12.4 127.4 ± 12.1 131.1 ± 12.0 127.6 ± 12.2
Diastolic 75.6 ± 8.2 75.8 ± 7.7 77.4 ± 7.7 75.9 ± 7.9
*As measured by ofﬁce cuff sphygmomanometer.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; BP, blood pressure; OA, osteoarthritis; od, once
daily; SD, standard deviation; tid, thrice daily.
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antihypertensive treatments (ITT population)*
Parameter
LSM (SE) change from baseline at week 4
Estimated difference
(95% CI) p-Value N
Lumiracoxib
100 mg od N
Ibuprofen
600 mg tid
Overall population 363 )2.7 (0.4) 359 2.2 (0.4) )5.0 ()6.1 to )3.8) < 0.001
Subgroups
ARB
Monotherapy 53 )3.5 (1.2) 45 4.6 (1.3) )8.1 ()11.5, )4.7) < 0.001
Any use 138 )2.6 (0.7) 130 3.5 (0.8) )6.1 ()8.2, )4.0) < 0.001
ACEI
Monotherapy 39 )4.6 (1.3) 37 3.7 (1.4) )8.2 ()12.1, )4.4) < 0.001
Any use 105 )4.0 (0.7) 110 2.0 (0.7) )5.9 ()7.9, )3.9) < 0.001
Beta-blocker
Monotherapy 35 )3.0 (1.1) 22 2.8 (1.4) )5.8 ()9.3, )2.3) 0.002
Any use 109 )2.4 (0.7) 109 1.6 (0.7) )4.0 ()6.0, )2.1) < 0.001
Calcium channel blockers
Monotherapy 17 )1.0 (1.4) 17 1.8 (1.4) )2.8 ()6.9, 1.4) 0.184
Any use 85 )2.3 (0.7) 66 1.2 (0.8) )3.4 ()5.4, )1.5) < 0.001
Diuretic
Monotherapy 12 )1.5 (2.3) 17 2.1 (1.9) )3.6 ()9.8, 2.6) 0.241
Any use 183 )2.4 (0.6) 194 1.4 (0.6) )3.8 ()5.4, )2.3) < 0.001
Any
Monotherapy 156 )3.2 (0.6) 138 3.4 (0.7) )6.7 ()8.5, )4.9) < 0.001
Combination 206 )2.5 (0.5) 217 1.3 (0.5) )3.9 ()5.3, )2.4) < 0.001
*Primary end-point.
Monotherapy or free and ﬁxed-dose combinations.
Free or ﬁxed-dose.
ACEI, angiotensin-converting enzyme inhibitor; ARBs, angiotensin receptor blockers; CI, conﬁdence interval; MSABP, mean systolic
ambulatory blood pressure; ITT, intention-to-treat; LSM, least squares mean; od, once daily; SE, standard error; tid, thrice daily.
(A) (B)
Figure 1 Change in 24-h mean systolic ambulatory blood pressure (mmHg) and mean diastolic ambulatory blood pressure
(mmHg) from baseline with lumiracoxib and ibuprofen for 4 weeks in patients with well-controlled hypertension on (A)
angiotensin receptor blocker monotherapy and (B) angiotensin-converting enzyme inhibitor monotherapy (ITT
population). ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; Est. Diff., estimated
treatment difference; ITT, intention-to-treat; MDABP, mean diastolic ambulatory blood pressure; MSABP, mean systolic
ambulatory blood pressure; od, once daily; tid, three times daily. Treatment analysed using an analysis of covariance
(ANCOVA) with treatment as main effect and centre and baseline 24-h MSABP as covariates
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assessment periods at baseline and week 4 for
patients receiving an ARB as monotherapy or ACEIs
as monotherapy. For patients taking ACEI mono-
therapy, the LSM change from baseline in 24-h
MSABP after 4 weeks of treatment fell by 4.6 mmHg
with lumiracoxib 100 mg od and increased by
3.7 mmHg with ibuprofen 600 mg tid, resulting in a
statistically signiﬁcant estimated treatment difference
of 8.2 mmHg in favour of lumiracoxib (Figure 1B;
Table 3). These treatment differences in 24-h MSABP
were greater than that observed in the overall ITT
population ()2.7 mmHg decrease with lumiracoxib,
a 2.2 mmHg increase with ibuprofen, producing an
estimated treatment difference of 5 mmHg in favour
of lumiracoxib). For patients receiving beta-blockers
as monotherapy, there was a signiﬁcant estimated
treatment difference of 5.8 mmHg in 24-h MSABP
in favour of lumiracoxib (Table 3). The use of
diuretics or calcium channel blockers as monothera-
py was associated with smaller, non-signiﬁcant treat-
ment differences in 24-h MSABP in favour of
lumiracoxib (Table 3). For all antihypertensive
monotherapy, there was an estimated treatment dif-
ference of 6.7 mmHg in favour of lumiracoxib for
24-h MSABP (Table 3). For any use of each antihy-
pertensive class, including monotherapy and combi-
nations, the 24-h MSABP at week 4 was signiﬁcantly
lower with lumiracoxib than with ibuprofen
(Table 3). The estimated difference in 24-h MSABP
between lumiracoxib and ibuprofen was 3.9 mmHg
(in favour of lumiracoxib) for all patients receiving
combination antihypertensive therapy (Table 3).
Lumiracoxib 100 mg od had lower 24-h MDABP
compared with ibuprofen 600 mg tid after the
4-week treatment resulting in a statistically signi-
ﬁcant estimated treatment difference of 3.7 mmHg
in favour of lumiracoxib in patients taking ARBs
only ()2.5 mmHg with lumiracoxib 100 mg od;
+1.3 mmHg with ibuprofen 600 mg tid [p < 0.001];
Figure 1 and Table 3) and 4.0 mmHg in favour of
lumiracoxib in patients receiving ACEIs only
()2.0 mmHg with lumiracoxib 100 mg od and
+2.0 mmHg with ibuprofen 600 mg tid [p = 0.003];
Table 3). Lumiracoxib 100 mg od also demonstrated
statistically signiﬁcantly lower daytime and night-
time MSABP and MDABP than ibuprofen in patients
taking ARBs or ACEIs only (Table 4).
For patients receiving ARBs as monotherapy, the
proportion of patients with a clinically relevant
increase in BP was signiﬁcantly greater for ibuprofen
(33.3%) vs. lumiracoxib (5.7%) (odds ratio [OR]
0.12; 95% CI 0.0, 0.4; p = 0.002). The incidence of
uncontrolled hypertension was smaller for lumirac-
(A) (B)
(C) (D)
Figure 2 Change in mean systolic ambulatory blood pressure (A, C) and mean diastolic ambulatory blood pressure (B, D)
with lumiracoxib and ibuprofen over the 24-h assessment periods (mmHg) at baseline and week 4 in patients with well-
controlled hypertension on ARB monotherapy (A, B) or ACE monotherapy (C, D). ACEI, angiotensin-converting enzyme
inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; MDABP, mean diastolic ambulatory blood pressure;
MSABP, mean systolic ambulatory blood pressure; od, once daily; tid, thrice daily
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ence was not statistically signiﬁcant (OR 0.22; 95%
CI 0.0, 1.2; p = 0.077).
The proportion of patients with a clinically rele-
vant increase in BP was 21.6% for ibuprofen vs.
12.8% for lumiracoxib for patients receiving ACEIs
as monotherapy, although the difference between
treatment groups did not reach statistical signiﬁcance
(OR 0.63; 95% CI 0.2, 2.3; p = 0.486). The inci-
dence of uncontrolled hypertension was smaller for
Table 4 Summary of the ambulatory BP measurement assessments (mmHg) for patients receiving angiotensin receptor
blockers or an angiotensin-converting enzyme inhibitor monotherapy at week 4 (ITT population)
Parameter
LSM (SE) change from baseline at week 4
Estimated difference
(95% CI) p-Value N
Lumiracoxib
100 mg od N
Ibuprofen
600 mg tid
24-h MDABP*
ARB monotherapy 53 )2.5 (0.6) 45 1.3 (0.7) )3.7 ()5.6, )1.9) < 0.001
ACEI monotherapy 39 )2.0 (0.9) 37 2.0 (0.9) )4.0 ()6.6, )1.4) 0.003
Daytime MSABP*
ARB monotherapy 53 )3.1 (1.3) 45 5.2 (1.4) )8.3 ()12.2, )4.5) < 0.001
ACEI monotherapy 39 )5.3 (1.6) 37 4.1 (1.6) )9.4 ()13.9, )4.9) < 0.001
Night-time MSABP*
ARB monotherapy 53 )3.9 (1.2) 45 3.3 (1.3) )7.2 ()10.6, )3.8) < 0.001
ACEI monotherapy 39 )2.9 (1.39) 37 2.5 (1.42) )5.4 ()9.4, )1.4) 0.008
Daytime MDABP*
ARB monotherapy 53 )2.2 (0.8) 45 1.4 (0.8) )3.6 ()5.8, )1.4) 0.001
ACEI monotherapy 39 )2.4 (1.1) 37 1.9 (1.1) )4.3 ()7.4, )1.1) 0.009
Night-time MDABP*
ARB monotherapy 53 )2.8 (0.7) 45 0.9 (0.7) )3.7 ()5.6, )1.8) < 0.001
ACEI monotherapy 39 )1.0 (1.0) 37 1.9 (1.0) )2.8 ()5.7, 0.0) 0.049
*Change from baseline at week 4.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; BP, blood pressure; CI, conﬁdence interval; ITT,
intention-to-treat; LSM, least squares mean; MDABP, mean diastolic ambulatory blood pressure; MSABP, mean systolic ambulatory
blood pressure; od, once daily; SE, standard error; tid, three times daily.
Table 5 Summary of patients improving efﬁcacy variables on lumiracoxib and ibuprofen treatment at week 4 in
subgroups of patients receiving angiotensin receptor blockers or an angiotensin-converting enzyme inhibitor
monotherapy (ITT population)
Parameter
Patients improving score [n⁄N (%)]
Odds ratio
(95% CI) p-Value
Lumiracoxib
100 mg od
Ibuprofen
600 mg tid
OA pain
ARB monotherapy 35⁄56 (62.5) 33⁄47 (70.2) Not calculable* 0.531*
ACEI monotherapy 31⁄41 (75.6) 21⁄39 (53.8) 3.05 (1.1, 8.4) 0.032
Patient’s global assessment of disease activity
ARB monotherapy 33⁄56 (58.9) 28⁄47 (59.6) 0.61 (0.2, 1.6) 0.298
ACEI monotherapy 25⁄41 (61.0) 18⁄39 (46.2) Not calculable* 0.262*
Physician’s global assessment of disease activity
ARB monotherapy 36⁄56 (64.3) 31⁄47 (66.0) Not calculable* > 0.999*
ACEI monotherapy 24⁄41 (58.5) 21⁄39 (53.8) 1.03 (0.3, 3.0) 0.955
In this analysis, treatment was the main effect and respective baseline variable was the covariate.
*If the model did not converge, the p-value was obtained using Fisher’s exact test.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; CI, conﬁdence interval; ITT, intention-to-treat; od,
once daily; tid, thrice daily.
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this difference was not statistically signiﬁcant (OR
0.25; 95% CI 0.0, 1.6; p = 0.142).
In the overall study population, lumiracoxib
100 mg od and ibuprofen 600 mg tid treatment had
comparable effects on measures of efﬁcacy (pain
intensity, patient’s global assessment of disease
activity and physician’s global assessment of disease
activity) (10). Similarly, in the ARB as monotherapy
subgroup, there was no signiﬁcant difference in
efﬁcacy between treatments (Table 5). For patients
receiving ACEIs as monotherapy, the patient’s global
assessment of disease activity and the physician’s glo-
bal assessment of disease activity were not statistically
different between lumiracoxib and ibuprofen. How-
ever, more patients had improvements in their OA
pain intensity with lumiracoxib compared with
ibuprofen (p = 0.032) in the ACEI monotherapy
subgroup.
Discussion
This post hoc analysis suggests that lumiracoxib
100 mg od results in less destabilisation of SBP and
DBP compared with high-dose ibuprofen 600 mg tid
after the 4-week treatment in hypertensive OA
patients aged ‡ 50 years, particularly when treated
with an ARB or an ACEI monotherapy. Patients trea-
ted with an ARB or an ACEI represented the largest
subgroups receiving antihypertensive monotherapy
and the difference in LSM 24-h MSABP between
lumiracoxib and ibuprofen was greater in these
patients (ARB, )8.1 mmHg; ACEI, )8.2 mmHg)
than for the overall population ()5.0 mmHg) (10).
A signiﬁcant difference in 24-h MSABP in favour of
lumiracoxib was also observed in patients receiving
beta-blocker monotherapy ()5.8 mmHg). For the
calcium channel blockers and diuretic monotherapy
subgroups, treatment differences were smaller than
in the overall study population and in the ARB and
ACEI monotherapy subgroups.
Previous studies have noted that NSAIDs can
increase BP in patients receiving antihypertensive
medication (1,2,7,8). The effects of NSAIDs and
COX-2 inhibitors on increasing BP would appear to
differ by the class of antihypertensive medication.
We used 600 mg of ibuprofen tid in the present
study, which can be considered high-dose, although
the over-the-counter dose is 400 mg tid and the
maximum daily dose prescribed is 2.4 g daily in the
UK.
In the present study, treatment with an ARB or
an ACEI was associated with the greatest treatment
differences in 24-h MSABP between lumiracoxib and
ibuprofen. Other studies would indicate that the
antihypertensive effect of ARBs and ACEIs is partic-
ularly susceptible to interference by NSAIDs (7,16).
The mechanism behind the interference of the
antihypertensive effect of ARBs and ACEIs by
NSAIDs is not clear from our study. However, given
the similar magnitudes of the treatment differences
with these antihypertensive classes and their mecha-
nisms of action on the renin-angiotensin-aldosterone
system, it seems probable that a common mediator,
angiotensin II, is involved. Indeed, inhibition of
prostaglandins has been reported to increase the
sensitivity of renal blood vessels to angiotensin II
(17). In healthy subjects, indomethacin has also been
shown to abolish the natriuretic effect of an ARB or
an ACEI therapy (18), and both these agents are
equally susceptible to the deterioration in renal
function with cyclo-oxygenase inhibition (19).The
nature of the cyclo-oxygenase inhibitor is also an
important factor, as evidenced by the treatment
differences observed between lumiracoxib and
ibuprofen in the current study. In the Successive
Celecoxib Efﬁcacy and Safety (SUCCESS)-VII
study, rofecoxib was noted to increase BP more
than celecoxib in patients treated with an ACEI or a
beta-blocker, although there were no differences in
BP between these COX-2 inhibitors in patients
treated with a diuretic or a calcium channel
blockers (4). The data reported from this study
is consistent with the SUCCESS-VII study showing
the greatest treatment differences with ARBs and
ACEIs.
Antihypertensive monotherapy was associated with
a greater difference in 24-h MSABP between lumirac-
oxib and ibuprofen than treatment with antihyper-
tensive combinations ()6.7 mmHg vs. )3.9 mmHg).
This is because the combinations tended to contain
calcium antagonists or diuretics, drug classes that
may be less affected by NSAIDs (20). This greater
treatment difference with monotherapy also reﬂects
the observation that ACEIs and ARBs comprised the
majority of the monotherapy population.
The antihypertensive effect of calcium channel
blockers appeared to be attenuated to a lesser extent
by NSAID treatment. An ABPM study has shown
that indomethacin increases BP more in patients
treated with the ACE inhibitor, enalapril, than in
patients receiving the calcium channel blockers,
amlodipine (8). Another study has also reported that
ibuprofen did not signiﬁcantly increase BP in
patients treated with the calcium channel blockers,
verapamil (21). Numbers of patients in the calcium
channel blocker subgroup of our study may have
been too small to detect signiﬁcant differences in
ambulatory BP between lumiracoxib and ibuprofen
in the present study.
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diuretic therapy would seem to indicate that the efﬁ-
cacy of these agents could be interfered with by NSA-
IDs. In a 4-week study, treatment with ibuprofen was
reported to increase BP in patients treated with hydro-
chlorothiazide (22). Similarly, ibuprofen has been
observed to increase SBP in elderly hypertensive
patients on hydrochlorothiazide treatment (3).
As expected, given the difﬁculties of achieving BP
control, more patients were receiving multiple anti-
hypertensive therapies compared with monotherapy.
Although diuretics represented the smallest subgroup
for antihypertensive monotherapy in our study, they
were the most commonly used agent in combina-
tions and overall reﬂecting their status as a preferred
and least expensive antihypertensive agent (23) with
additive antihypertensive efﬁcacy (24).
A recent meta analysis has indicated that lumirac-
oxib has a BP proﬁle similar to placebo (25), sug-
gesting that the difference in BP between
lumiracoxib and ibuprofen in the current study is
likely to be as a consequence of an adverse effect of
ibuprofen on BP rather than an antihypertensive
effect of lumiracoxib. Paracetamol treatment is
known to increase BP (26) and therefore the fall in
BP from baseline when paracetamol was replaced by
lumiracoxib at the end of the 1-week run-in period
would most likely indicate that lumiracoxib has a
neutral BP proﬁle. We cannot exclude that this BP
fall was caused by prior withdrawal of NSAID ther-
apy upon entry into the study or by withdrawal of
paracetamol therapy given during the washout phase.
It would have been good to have had a placebo trea-
ted arm in this study, but there were ethical issues
surrounding the use of placebo in a group of
patients requiring analgesia.
It remains unclear why there should be differences
between lumiracoxib and high-dose ibuprofen on
BP. Differences in pharmacokinetic and dosing regi-
men might be a possible explanation. For example,
although both agents have a short half-life, the expo-
sure of renal and cardiovascular tissues to ibuprofen
might be greater as a result of the more frequent
dosing regimen (tid). In contrast, lumiracoxib
100 mg was administered od, a regimen where it has
previously been shown to be effective in treating OA
pain (13,14).
Given that the incidence of hypertension is greater
in patients with OA than in the general population
(27), minimising interactions between OA treatments
and antihypertensive agent inhibitors might have
beneﬁts on the burden of healthcare. Indeed, avoid-
ing signiﬁcant increases in BP may have considerable
long-term beneﬁts for patients requiring chronic
NSAID therapy for OA pain and should circumvent
the need for additional BP monitoring and adjust-
ments of antihypertensive medications. NSAIDs and
selective COX-2 inhibitors have effects on systems
other than BP, and therefore there is potential
impact on toxicity in other organs. For example, it is
known that lumiracoxib and other COX-2 inhibitors
reduce the incidence of serious gastrointestinal ulcer
complications compared with non-selective NSAIDs
(28,29).
A possible weakness of this analysis includes the
fact that it was an exploratory and not a prespeciﬁed
analysis of the original study. At the time of the
randomization, there was no stratiﬁcation according
to these subgroups of antihypertensive agents; never-
theless, the distribution of therapies between treat-
ments among subgroups was quite well distributed.
Moreover, the numbers of patients receiving mono-
therapy with some classes of antihypertensive medi-
cations were small and could therefore confound
drawing meaningful conclusions from this analysis.
Finally, results presented in this manuscript are
drawn from a 4-week study. This may not be long
enough to draw deﬁnitive conclusions on the long-
term cardiovascular outcome of treatment with lumi-
racoxib as compared with ibuprofen.
In conclusion, lumiracoxib 100 mg od resulted in
less destabilisation of BP than high-dose ibuprofen
600 mg tid. This effect was maintained in most anti-
hypertensive subgroups and was most pronounced in
individuals receiving ARBs or ACEIs, the largest of
the monotherapy subgroups.
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